Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

2.

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.

Delsing Malmberg E, Johansson Alm S, Nicklasson M, Lazarevic V, Ståhlman S, Samuelsson T, Lenhoff S, Asp J, Ehinger M, Palmqvist L, Brune M, Fogelstrand L.

Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910. [Epub ahead of print]

PMID:
30068244
3.

Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - A Swedish nationwide cohort study.

Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Brune M, Andersson PO.

Eur J Haematol. 2018 Jun;100(6):613-620. doi: 10.1111/ejh.13057. Epub 2018 Apr 10.

PMID:
29532518
4.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT.

Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden JA, Itälä-Remes M, Musso M, van Biezen A, Garderet L, Kröger N.

Haematologica. 2018 May;103(5):890-897. doi: 10.3324/haematol.2017.178434. Epub 2018 Feb 1.

5.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N.

Biol Blood Marrow Transplant. 2018 May;24(5):930-936. doi: 10.1016/j.bbmt.2018.01.006. Epub 2018 Jan 12.

6.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N.

Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.

7.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.

PMID:
29196078
8.

Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).

Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, Schaap N, Cornelissen JJ, Maillard N, Pioltelli P, Gedde-Dahl T, Lenhoff S, Houhou M, Esteve J, Mohty M, Nagler A.

Am J Hematol. 2018 Jan;93(1):31-39. doi: 10.1002/ajh.24928. Epub 2017 Oct 31.

9.

Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.

Pahnke S, Larfors G, Axdorph-Nygell U, Fischer-Nielsen A, Haastrup E, Heldal D, Itälä-Remes M, Johansson JE, Kauppila M, Lenhoff S, Ljungman P, Niittyvuopio R, Sandstedt A, Hägglund H.

J Clin Apher. 2018 Jun;33(3):226-235. doi: 10.1002/jca.21576. Epub 2017 Aug 18.

PMID:
28833474
10.

Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011.

Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, Uggla B, Winiarski J, Ljungman P, Brune M, Andersson PO.

Haematologica. 2017 Oct;102(10):1683-1690. doi: 10.3324/haematol.2017.169862. Epub 2017 Jul 27.

11.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.

Rosengren S, Mellqvist UH, Nahi H, Forsberg K, Lenhoff S, Strömberg O, Ahlberg L, Linder O, Carlson K.

Bone Marrow Transplant. 2016 Dec;51(12):1569-1572. doi: 10.1038/bmt.2016.249. Epub 2016 Oct 3.

PMID:
27694943
12.

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.

Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050.

13.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socié G, Bruno B, Meijer E, Mufti GJ, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1615-1620. doi: 10.1016/j.bbmt.2016.05.026. Epub 2016 Jun 3.

14.

Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.

Lübking A, Vosberg S, Konstandin NP, Dufour A, Graf A, Krebs S, Blum H, Weber A, Lenhoff S, Ehinger M, Spiekermann K, Greif PA, Cammenga J.

Leuk Res Rep. 2015 Oct 17;4(2):72-5. doi: 10.1016/j.lrr.2015.10.001. eCollection 2015.

15.

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.

Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation.

Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8.

16.

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist UH, Linder O, Lindås R, Tøffner Clausen N, Lenhoff S.

Bone Marrow Transplant. 2015 Oct;50(10):1306-11. doi: 10.1038/bmt.2015.125. Epub 2015 Jun 29.

17.

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.

Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson BM, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, Lenhoff S, Masson G, Mellqvist UH, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, Nahi H, Gudbjartsson DF, Rafnar T, Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B.

Nat Commun. 2015 May 26;6:7213. doi: 10.1038/ncomms8213.

18.

Being a haematopoietic stem cell donor for a sick sibling: Adult donors' experiences prior to donation.

Kisch A, Bolmsjö I, Lenhoff S, Bengtsson M.

Eur J Oncol Nurs. 2015 Oct;19(5):529-35. doi: 10.1016/j.ejon.2015.02.014. Epub 2015 Mar 23.

PMID:
25813531
19.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M.

Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.

20.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide.

Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff GW, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kroger N, de Witte T, Ruutu T; Chronic Malignancies and Lymphoma Working Parties of EBMT.

Transfusion. 2014 Oct;54(10):2514-22. doi: 10.1111/trf.12759. Epub 2014 Jun 26.

PMID:
24964911
21.

Having a sibling as donor: patients' experiences immediately before allogeneic hematopoietic stem cell transplantation.

Kisch A, Bolmsjö I, Lenhoff S, Bengtsson M.

Eur J Oncol Nurs. 2014 Aug;18(4):436-42. doi: 10.1016/j.ejon.2014.03.004. Epub 2014 Apr 8.

PMID:
24721180
22.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hägglund H, Carlson K, Fagius J.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21. doi: 10.1136/jnnp-2013-307207. Epub 2014 Feb 19.

PMID:
24554104
23.

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.

Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

24.

Potential adult sibling stem cell donors' perceptions and opinions regarding an information and care model.

Kisch A, Lenhoff S, Bengtsson M, Bolmsjö I.

Bone Marrow Transplant. 2013 Aug;48(8):1133-7. doi: 10.1038/bmt.2012.283. Epub 2013 Jan 21.

PMID:
23334271
25.

Factors associated with changes in quality of life in patients undergoing allogeneic haematopoietic stem cell transplantation.

Kisch A, Lenhoff S, Zdravkovic S, Bolmsjö I.

Eur J Cancer Care (Engl). 2012 Nov;21(6):735-46. doi: 10.1111/j.1365-2354.2012.01354.x. Epub 2012 Apr 23.

PMID:
22519415
26.

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.

Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, Lenhoff S, Sanz MA, Aljurf M, Mohty M, Rocha V; Immunotherapy Subcommittee of Acute Leukemia Working Party.

Leukemia. 2012 Jun;26(6):1211-7. doi: 10.1038/leu.2011.351. Epub 2012 Jan 31.

PMID:
22290066
27.

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.

Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Güngör T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P, Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D; EBMT Autoimmune Disease Working Party.

Blood. 2011 Aug 11;118(6):1693-8. doi: 10.1182/blood-2011-02-336156. Epub 2011 May 19.

28.

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries.

Abelsson J, Merup M, Birgegård G, WeisBjerrum O, Brinch L, Brune M, Johansson P, Kauppila M, Lenhoff S, Liljeholm M, Malm C, Remes K, Vindelöv L, Andréasson B; Nordic MPD Study Group.

Bone Marrow Transplant. 2012 Mar;47(3):380-6. doi: 10.1038/bmt.2011.91. Epub 2011 May 9.

PMID:
21552298
29.

Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.

Johnsen HE, Klausen TW, Boegsted M, Lenhoff S, Gimsing P, Christiansen I, Gedde-Dahl T, Lindås R, Mellqvist UH; Nordic Myeloma Study Group.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):290-6. doi: 10.3816/CLML.2010.n.060.

PMID:
20709667
30.

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.

Johnsen HE, Bøgsted M, Klausen TW, Gimsing P, Schmitz A, Kjaersgaard E, Damgaard T, Voss P, Knudsen LM, Mylin AK, Nielsen JL, Björkstrand B, Gruber A, Lenhoff S, Remes K, Dahl IM, Fogd K, Dybkaer K; Nordic Myeloma Study (NMSG); Myeloma Stem Cell Network (MSCNET).

Cytometry B Clin Cytom. 2010 Sep;78(5):338-47. doi: 10.1002/cyto.b.20523. Epub 2010 Apr 28.

31.

High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.

Toporski J, Garkavij M, Tennvall J, Ora I, Gleisner KS, Dykes JH, Lenhoff S, Juliusson G, Scheding S, Turkiewicz D, Békássy AN.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1077-85. doi: 10.1016/j.bbmt.2009.05.007. Epub 2009 Jul 8.

32.

Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT.

Chalandon Y, Passweg JR, Schmid C, Olavarria E, Dazzi F, Simula MP, Ljungman P, Schattenberg A, de Witte T, Lenhoff S, Jacobs P, Volin L, Iacobelli S, Finke J, Niederwieser D, Guglielmi C; Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2010 Mar;45(3):558-64. doi: 10.1038/bmt.2009.177. Epub 2009 Jul 27.

PMID:
19633691
33.

Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.

Ghatnekar O, Alvegård T, Conradi N, Lenhoff S, Mellqvist UH, Persson U, Löthgren M.

Clin Ther. 2008 Sep;30(9):1704-13. doi: 10.1016/j.clinthera.2008.09.003.

PMID:
18840377
34.

A proposed plan for the management of adult sibling donors.

Kisch A, Dykes J, Lindmark A, Lenhoff S.

Bone Marrow Transplant. 2008 Sep;42(5):357-8. doi: 10.1038/bmt.2008.172. Epub 2008 Jun 23. No abstract available.

PMID:
18574448
36.
37.

Cytogenetic evolution patterns in CML post-SCT.

Karrman K, Sallerfors B, Lenhoff S, Fioretos T, Johansson B.

Bone Marrow Transplant. 2007 Feb;39(3):165-71. Epub 2007 Jan 8.

PMID:
17211433
38.

Serum calcium is an independent predictor of quality of life in multiple myeloma.

Wisløff F, Kvam AK, Hjorth M, Lenhoff S.

Eur J Haematol. 2007 Jan;78(1):29-34. Epub 2006 Oct 13.

PMID:
17038019
39.

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerström J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL; Nordic Myeloma Study Group.

Haematologica. 2006 Sep;91(9):1228-33.

40.

Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.

Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE; Nordic Myeloma Study Group.

Eur J Haematol. 2006 Nov;77(5):416-24. Epub 2006 Aug 23.

PMID:
16930142
41.

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.

Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, Martino R, Bengala C, Brune M, Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D, Ringdén O; French ITAC group and the EBMT Solid Tumour Working Party.

Ann Oncol. 2006 Jul;17(7):1134-40. Epub 2006 Apr 28.

PMID:
16648196
42.

Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.

Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I; Nordic Myeloma Study Group.

Br J Haematol. 2006 May;133(4):389-96.

PMID:
16643445
43.

Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients.

Roer O, Hammerstrøm J, Lenhoff S, Mylin AK, Knudsen LM, Rasmussen T, Johnsen HE; Nordic Myeloma Study Group.

Cytotherapy. 2006;8(1):79-88.

PMID:
16637135
44.

Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.

Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D; European Bone Marrow Transplantation Solid Tumor Working Party.

Cancer. 2005 Nov 15;104(10):2099-103.

45.

Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.

Wisløff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P.

Eur J Haematol. 2005 Oct;75(4):293-8.

PMID:
16146535
46.

MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).

Nilsson T, Nilsson L, Lenhoff S, Rylander L, Astrand-Grundström I, Strömbeck B, Höglund M, Turesson I, Westin J, Mitelman F, Jacobsen SE, Johansson B.

Genes Chromosomes Cancer. 2004 Nov;41(3):223-31.

PMID:
15334545
47.

High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation.

Nilsson T, Lenhoff S, Rylander L, Höglund M, Turesson I, Mitelman F, Westin J, Johansson B.

Br J Haematol. 2004 Aug;126(4):487-94.

PMID:
15287940
48.

Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.

Passweg JR, Rabusin M, Musso M, Beguin Y, Cesaro S, Ehninger G, Espigado I, Iriondo A, Jost L, Koza V, Lenhoff S, Lisukov I, Locatelli F, Marmont A, Philippe P, Pilatrino C, Quartier P, Stary J, Veys P, Vormoor J, Wahlin A, Zintl F, Bocelli-Tyndall C, Tyndall A, Gratwohl A; Autoimmune Disease Working Party of the EBMT.

Br J Haematol. 2004 Jun;125(6):749-55.

49.

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.

Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wislöff F; Nordic Myeloma Study Group.

Br J Haematol. 2004 Apr;125(2):149-55.

PMID:
15059136
50.

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Børset M, Sundan A, Hjertner O.

Haematologica. 2004 Feb;89(2):174-82.

Supplemental Content

Loading ...
Support Center